Real-World Outcomes of Tisagenlecleucel and Consolidative Hematopoietic Cell Transplantation in Pediatric Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Objectives: Chimeric antigen receptor (CAR) T-cell therapy induces high remission rates in pediatric relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but the durability of remission and the role of consolidative hematopoietic cell transplantation (HCT) in heavily pretreated patients remain unresolved. We evaluated real-world outcomes of CAR T-cell therapy and the feasibility of consolidative HCT. Methods: We retrospectively analyzed 30 children and adolescents with R/R B-ALL who received commercial tisagenlecleucel at a single center. Survival outcomes were compared according to consolidative HCT using a time-dependent Cox model to account for immortal-time bias. Results: Of the 30 patients, 18 (60.0%) had undergone prior allogeneic HCT and 19 (63.3%) had a high disease burden. The 1-month overall response rate was 73.3%, with measurable residual disease-negative remission in 21 patients (95.5% of responders). With a median follow-up of 19.5 months, the 1-year event-free survival (EFS) and overall survival (OS) were 57.2 ± 9.6% and 55.5 ± 9.8%, respectively. One-year relapse-free survival among responders was 77.9 ± 9.9% (67.5 ± 17.2% when censored at HCT). Patients with ≥2 prior relapses had significantly inferior EFS and OS. Twelve of 22 responders (54.5%) underwent consolidative HCT, including 6 who had prior transplantations, with no subsequent relapse; however, no statistically significant survival advantage was observed, and transplanted responders had fewer prior relapses than those who were not transplanted. Conclusions: Treatment failure occurred mainly in patients who did not achieve remission. Consolidative HCT, including second transplantation, was feasible, but its benefit remains uncertain, and which responders require consolidation remains to be defined.
Source: Cancers
Authors: Jae Won Yoo(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft), Suejung Jo(Data curation, Formal analysis, Investigation), Seongkoo Kim(Formal analysis, Investigation), Jae Wook Lee(Conceptualization, Funding acquisition, Investigation, Supervision, Writing – review & editing), Nack-Gyun Chung(Formal analysis, Investigation, Writing – review & editing), Bin Cho(Formal analysis, Writing – review & editing)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
Award: G9001398561
OpenAlex ID: W7236655571
